Cure Pharmaceutical (OTCQB: CURR) is a fully integrated specialty pharmaceutical/bioscience company with disruptive proprietary drug delivery technologies for a broad range of molecules serving the pharmaceutical, biotech, veterinarian, medical foods markets, cannabinoid molecules and new chemical entities (NCEs). Cure has an industry leading full service cGMP manufacturing facility and is a preeminent developer and manufacturer of a patented and proprietary delivery system (CureFilm™), the most advanced oral thin film on the market today. Alongside its stand-alone CureFilm™ technology, Cure has developed an array of products in cutting-edge delivery platforms, such as sublingual and transdermal applications. The Company leverages novel drug delivery technologies to develop and commercialize new applications of proven therapeutics and also partners with pharmaceutical and biotech companies looking for new methods to deliver their proprietary molecules. The Cure team has extensive experience formulating and manufacturing OTC products, pharmaceuticals, and veterinary medications placing quality and service as its top priorities, thus earning it the trust and respect of customers worldwide. Cure is well positioned in the pharmaceutical cannabis sector and is developing a global footprint with partners in the U.S., Israel and Germany, among other markets, including a recent research collaboration agreement with CannaKids to develop cannabinoid and terpene molecules using Cure’s proprietary drug delivery technologies. The Company’s mission is to create solutions to improve the overall quality of life and deliver proven drugs in a fast and efficient manner. The Company’s team continues to develop new formulations, encapsulation processes, and delivery systems to improve efficacy, access, sustainability, and the overall quality of life.
